1. Introduction {#sec1-molecules-22-00924}
===============

Natural products have played a highly significant role in the medicine discovery and development processes and many useful medicines were developed from plant sources \[[@B1-molecules-22-00924]\]. This was particularly evident in the area of cancer treatment, where over 60% of current antitumor drugs, such as vinblastine, etoposide and paclitaxel, originated from Nature \[[@B2-molecules-22-00924]\].

Glycyrrhetinic acid (**GA**, [Figure 1](#molecules-22-00924-f001){ref-type="fig"}) is a triterpenoid aglycone component of the natural product glycyrrhizinic acid (**GL**), which is abundant in licorice root \[[@B3-molecules-22-00924]\]. **GA** was proved to possess a variety of remarkable biological activities, including anti-inflammatory \[[@B4-molecules-22-00924],[@B5-molecules-22-00924]\], antiviral \[[@B6-molecules-22-00924],[@B7-molecules-22-00924]\], hepato- protective \[[@B8-molecules-22-00924],[@B9-molecules-22-00924]\], and antitumor properties \[[@B10-molecules-22-00924],[@B11-molecules-22-00924]\]. **GA** is highly regarded for its remarkable antitumor activities, whereby it shows significant cytotoxic activity against a broad variety of different cell types in vitro, for example non-small cell lung cancer cells \[[@B11-molecules-22-00924]\], pituitary adenoma cells \[[@B12-molecules-22-00924]\], human hepatocellular carcinoma cells \[[@B13-molecules-22-00924]\], prostate cancer cells \[[@B14-molecules-22-00924]\] and glioblastoma cells \[[@B15-molecules-22-00924]\]. It also exhibits noteworthy activity in various experimental cancer models in vivo \[[@B16-molecules-22-00924],[@B17-molecules-22-00924]\], and it is known to trigger apoptosis in tumor cell lines \[[@B14-molecules-22-00924],[@B18-molecules-22-00924],[@B19-molecules-22-00924]\]. Some experimental reports have indicated that **GA** triggered apoptosis via the mitochondrial pathway through the collapse of mitochondrial membrane potential, the accumulation of the cytosolic cytochrome c and the activation of caspase-9 and caspase-3 \[[@B19-molecules-22-00924],[@B20-molecules-22-00924]\].

The remarkable antitumor activity of **GA** has been the focus of researchers worldwide. However, because **GA** can inhibit type 2 11ß-hydroxysteroid dehydrogenase (11ß-HSD2), administrating **GA** at a high dose for a long time often causes pseudoaldosteronism, which is characterized by hypertension, hypokalemia and other adverse clinical effects \[[@B21-molecules-22-00924],[@B22-molecules-22-00924],[@B23-molecules-22-00924]\]. Studies on using **GA** as a scaffold to develop new low-toxicity and high-effectivity antitumor agents have attracted much attention, and a number of structural modifications of **GA** were carried out and some reports of novel **GA** derivatives as antitumor agents have been published \[[@B24-molecules-22-00924],[@B25-molecules-22-00924],[@B26-molecules-22-00924]\]. This overview is dedicated to summarizing and updating four aspects of the structural modification of **GA** leading to antitumor agents published between 2005 and 2016, including modifications at the ring-A, ring-C, ring-E and multiple ring modification. We have compiled the most active **GA** derivatives along with their activity profile in different series. Furthermore, the structure activity relationships of these derivatives are briefly discussed.

2. Four Aspects of the Structural Modifications of Glycyrrhetinic Acid {#sec2-molecules-22-00924}
======================================================================

In the past few years, plenty of researchers around the world have designed and synthesized series of **GA** derivatives as potential antitumor agents. Most reports about the chemical and structural modifications of **GA** were focused on the specific functional groups of the A, C, and E rings, as these three rings contain three functional groups which are the most suitable for modification: a hydroxyl group at C-3 in ring-A, an α,β-unsaturated carbonyl function located in ring-C at C-11 and a carboxyl group at C-30 on ring-E. Meanwhile, studies on the skeleton ring architecture modification of this pentacyclic triterpene are increasing too, hence, the modifications of **GA** to produce novel antitumor agents can be classified into four styles, including structural modifications at ring-A, at ring-C, at ring-E and at multiple ring modifications.

2.1. Structural Modifications on Ring-A {#sec2dot1-molecules-22-00924}
---------------------------------------

### 2.1.1. Structural Modifications at the C3-OH in Ring-A {#sec2dot1dot1-molecules-22-00924}

The structural modifications at the C3-OH group of **GA** are very common. For example, it could be converted into an oxime group, a carbonyl group and a 3-oxo group. However, in order to change the polarity pattern or improve the antitumor activity of **GA**, the C-30 carboxyl group was often esterified too.

It was reported that changing the polarity pattern of **GA** might be an advantage in obtaining better cytotoxicity. Based on this, different C-3 amino alkyl derivatives of **GA** (compounds **4**--**11**, [Scheme 1](#molecules-22-00924-sch001){ref-type="scheme"}, were synthesized by Csuk et al. \[[@B27-molecules-22-00924]\]. The antitumor activity of these derivatives was tested in a panel of 15 human cancer cell lines by a SRB assay. In the SRB assay, all of the amino compounds **4**--**11** showed significantly improved activity compared with **GA**. Among them, it could be observed that a diaminohexyl chain with seven carbon atoms was the most active derivative, about 60 times more so than **GA**. The antitumor activity was changed with the change of the carbon number. The results also showed that the esterification at C-30 (compound **3**, [Scheme 1](#molecules-22-00924-sch001){ref-type="scheme"}) could improve the antitumor efficacy compared with compound **2**. The same result could be found from previous findings and parallel results \[[@B28-molecules-22-00924],[@B29-molecules-22-00924],[@B30-molecules-22-00924],[@B31-molecules-22-00924],[@B32-molecules-22-00924]\]. Besides, the introduction of nitrogen-containing substituents to the ring-A seemed to improve the anti-proliferative effect of **GA** derivatives. The cytotoxicity (IC~50~ values in μmol) of **1**--**11** in a panel of various cancer cell lines is summarized in [Table 1](#molecules-22-00924-t001){ref-type="table"}.

Similarly, in order to change the polarity pattern of **GA**, Schwarz et al. \[[@B33-molecules-22-00924]\] prepared a series of novel derivatives **12**--**32** by introducing an extra amino group into C-3 and esterifying at C-30 ([Scheme 2](#molecules-22-00924-sch002){ref-type="scheme"}). These derivatives showed a higher antitumor activity and a better selectivity towards tumor cells compared with **GA** on 15 different human tumor cell lines and mouse embryonic fibroblasts (NiH3T3). Compound **24** substituted with glycine and esterified with an *i*-propyl moiety was the most active compound. As discussed above for antitumor activity, in this case, the esterification at C-30 also resulted in improved activity against tumor cell lines compared with **GA**. The most active compound among the C-30 ester derivatives was the benzyl ester (compound **14**) showing IC~50~ value between 6.15--23.82 µM. The decrease of the IC~50~ value paralleled the size and lipophilic character of the alkyl chain of the esters. From the SAR of these compounds, it was concluded that the introduction of an extra amino acid moiety at C3-OH or an alkyl group at C30-COOH could enhance the antitumor activity. There seemed to be no effect by adding a stereogenic center in the side chain according to the results. Besides, the amines and their respective ammonium salts might be considered bioequivalent in biological activity. The cytotoxicity (IC~50~ values in µM) of **12**--**32** in a panel of various cancer cell lines is summarized in [Table 2](#molecules-22-00924-t002){ref-type="table"}.

In subsequent research Csuk et al. conducted another study in a similar manner, producing a series of derivatives **33**--**44** substituted with aspartic and glutamic acid ([Scheme 3](#molecules-22-00924-sch003){ref-type="scheme"}) \[[@B34-molecules-22-00924]\]. The glutamic acid derivative **36** with a benzyl-protected side chain was the most active derivative among this series, showing an IC~50~ value between 1.27--2.33 µM. Meanwhile, compound **36** displayed an extraordinary selectivity (Mean F = 23) in comparison with other compounds. The derivatives carrying a free amino group and an unprotected carboxylic group such as compounds **39** and **40** turned out to be inactive (IC~50~ \> 100 µM). The cytotoxicity (IC~50~ values in µM) of **33**--**40**, **43**, **44** in a panel of various cancer cell lines is summarized in [Table 3](#molecules-22-00924-t003){ref-type="table"}.

As mentioned, introduction an extra amino group into C-3 and esterification at C-30 could improve the antitumor activity of **GA** derivatives. To further increase the cytotoxicity and improve the selectivity, some other amino acid derivatives of glycyrrhetinic acid **45**--**59** ([Scheme 4](#molecules-22-00924-sch004){ref-type="scheme"}) were designed and synthesized in a similar way by Csuk et al. \[[@B35-molecules-22-00924]\]. The derivatives possessing short side chains like the alanyloxy or sarcosyloxy moiety, turned out to exhibit higher cytotoxic activity, for example, compound **46** showed IC~50~ values between 1.83 and 3.42 µM. However compounds with a more lipophilic side chains, such as compound **50**, **51** showed decreased cytotoxic effects compared with **GA**--**Me** in the SRB assay. These results indicated that the structure of the amino acid side chain affected the cytotoxicity most. The cytotoxicity (IC~50~ values in µM) of **45**--**59** on a panel of various cancer cell lines is summarized in [Table 4](#molecules-22-00924-t004){ref-type="table"}.

It was reported that the introduction of an extra hydrophilic sugar moiety into betulinic acid could increase its cytotoxicity \[[@B36-molecules-22-00924]\]. Inspired by this, Schwarz et al. \[[@B37-molecules-22-00924]\] prepared some **GA** glycoside structural analogues **60**--**66** ([Scheme 5](#molecules-22-00924-sch005){ref-type="scheme"}) utilizing methyl glycyrrhetinate (compound **1**, [Scheme 1](#molecules-22-00924-sch001){ref-type="scheme"}) as starting material.

Their antitumor activity was evaluated in a SRB assay on various tumor cell lines. These derivatizations did not result in increased cytotoxicity, with the exception of compound **64** which showed IC~50~ values as low as 9.48 µM on breast carcinoma MCF-7 cells, which was twice the activity of **GA**--**Me**. It seemed that there was no correlation between the monosaccharide structure and the cytotoxicity, and similar results could also be found in \[[@B36-molecules-22-00924],[@B38-molecules-22-00924],[@B39-molecules-22-00924]\]. The cytotoxicity (IC~50~ values in µM) of **60**--**66** in a panel of various cancer cell lines is summarized in [Table 5](#molecules-22-00924-t005){ref-type="table"}.

Lai et al. \[[@B40-molecules-22-00924]\] designed and synthesized a series of novel furan-based nitric oxide (NO)-releasing derivatives of **GA 68**--**74** ([Scheme 6](#molecules-22-00924-sch006){ref-type="scheme"}) as antitumor agents. According to the MTT assay results, compounds **68**--**74** displayed increased anti-HCC (HepG2, BEL-7402) activity (IC~50~ 2.90--36.52 µM on HepG2, IC~50~ 2.94--19.92 µM on BEL-7402) compared with **GA** (IC~50~ \> 50 µM on HepG2, BEL-7402). The most active compound was **74**, showing IC~50~ values as low as 2.90 µM, 2.94 µM on HepG2 and BEL-7402, respectively. These findings might provide more information for the design of new chemotherapeutic reagents for the intervention on human HCC in the clinic. The cytotoxicity (IC~50~ values in µM) of **68**--**74** in a panel of various cancer cell lines is summarized in [Table 6](#molecules-22-00924-t006){ref-type="table"}.

After forming long chains with ester bonds at C-3, Kumar Yadav et al. \[[@B41-molecules-22-00924]\] found the **GA-1**, **GA-2** and **GA-3** ([Figure 2](#molecules-22-00924-f002){ref-type="fig"}) expressed significant antitumor activity against the human lung cancer cell line A-549 with pred. log IC~50~ = 1.182, 1.044, 1.274 µM according to the quantitative structure-activity relationship (QSAR) model. The cytotoxicity (IC~50~ values in µM) of **GA-1**, **GA-2** and **GA-3** on A-549 is summarized in [Table 7](#molecules-22-00924-t007){ref-type="table"}.

### 2.1.2. Structural Modifications at the Skeleton of Ring-A {#sec2dot1dot2-molecules-22-00924}

Previous studies revealed that some triterpenoid derivatives which contained a 2-cyano-1-en-3-one functionality on ring-A, such as the oleanoic acid derivatives **CDDO** ([Figure 3](#molecules-22-00924-f003){ref-type="fig"}) and its methyl ester **CDDO-Me** ([Figure 3](#molecules-22-00924-f003){ref-type="fig"}), exerted potent cytotoxic activity in various cancer cell lines \[[@B42-molecules-22-00924],[@B43-molecules-22-00924]\]. Similar results were also obtained with **GA** and betulinic acid derivatives containing a 2-cyano-1-en-3-one function, for example **β-CDODA-Me** \[[@B44-molecules-22-00924],[@B45-molecules-22-00924]\] ([Figure 3](#molecules-22-00924-f003){ref-type="fig"}). Inspired by this, Chadalapaka et al. \[[@B31-molecules-22-00924]\] synthesized some **β-CDODA-Me** analogs **75**--**79** ([Scheme 7](#molecules-22-00924-sch007){ref-type="scheme"}) with different electronegative 2-substituents including iodo, cyano, trifluoromethyl, dimethylphosphonyl and methanesulfonyl groups. The cell culture studies showed that the anti-proliferative activity of methyl derivative (**β-CDODA-Me**) on bladder and pancreatic cancer cells was more potent than that of the free acid (**β-CDODA**). This was consistent with a previous report \[[@B46-molecules-22-00924]\]. Among the derivatives, 2-cyano and 2-trifluoromethyl ones showed the highest anti-proliferation activity. However, compound **79** and compound **77** were relatively inactive, showing higher IC~50~ values ranging from 3.34 to 11.97 µM than the corresponding 2-cyano and 2-trifluoromethyl derivatives on the four cell lines. It could be seen that their relative potencies were dependent on the cell context: 2-trifluoromethyl derivative (compound **78**) (IC~50~ 0.38 µM in KU7, IC~50~ 0.82 µM in Panc-1, IC~50~ 1.14 µM in Panc-28) was more active than **β-CDODA-Me** (IC~50~ 1.59 µM in KU7, IC~50~ 1.22 µM in Panc-1, IC~50~ 1.80 µM in Panc-28), whereas **β-CDODA-Me** was more active in 253JB-V cells, showing IC~50~ values as low as 0.25 µM, lower than that of the compound **78 (**IC~50~ 0.67 µM). The results provided a new way for the structural modifications of **GA**. The cytotoxicity (IC~50~ values in μM) of **76**--**79** in a panel of various cancer cell lines is summarized in [Table 8](#molecules-22-00924-t008){ref-type="table"}.

In order to alter the lipophilicity of **GA**, several functional modifications were carried out at the C-2 and/or C-3 positions in ring-A by Csuk et al. \[[@B46-molecules-22-00924]\] and a series of derivatives **80**--**97** ([Scheme 8](#molecules-22-00924-sch008){ref-type="scheme"}) were obtained. Their cytotoxicity was investigated on eight different human tumor cell lines. According to the SRB assays, most of the derivatives showed lower antitumor activity than **GA**. Acetylated **GA** derivatives **80**--**82** and oxidized **GA** derivatives **83**--**85** did not show any significant antitumor activity. Deoxidized **GA** derivatives **86** and **97** were relatively active, showing IC~50~ \< 20 µM in several tested cancer cell lines. The cytotoxicity (IC~50~ values in μM) of **80**--**95**, **97** in a panel of various cancer cell lines is summarized in [Table 9](#molecules-22-00924-t009){ref-type="table"}.

In the search of new **GA** derivatives as antitumor agents, Jun et al. \[[@B47-molecules-22-00924]\] employed **GA** as precursor and synthesized a series of **GA** derivatives **98**--**112** ([Scheme 9](#molecules-22-00924-sch009){ref-type="scheme"}) with major changes to ring-A. The preliminary pharmacological study showed compound **98**, **100**, **101**, **105**, **106**, **110** with hydroxyl groups displayed some cytotoxicity on HepG-2. The derivative **105** with two hydroxyl groups at C-2 and C-3 displayed more potent activity than **GA** showing IC~50~ as low as 0.22 µM on HepG-2.

It seemed that the number and location of hydroxyl groups in ring-A had an important influence on the antitumor activity of **GA** derivatives. The cytotoxicity (IC~50~ values in μM) of **98**--**112** on HepG-2 os summarized in [Table 10](#molecules-22-00924-t010){ref-type="table"}.

2.2. Structural Modifications on Ring-C {#sec2dot2-molecules-22-00924}
---------------------------------------

The studies on structural modifications at ring-C were mainly focused on the carbonyl function located at C-11. According to Fiore and Salvi \[[@B48-molecules-22-00924],[@B49-molecules-22-00924]\], a ketone group at position C-11 was the primary cause for the apoptotic activity of **GA** derivatives, but the research conducted by Csuk et al. \[[@B50-molecules-22-00924]\] showed that there was no direct relation between the presence of the C-11 ketone group and the apoptotic activity of the compounds. Also, esterification at C-30 was important, as mentioned above. Six compounds ([Scheme 10](#molecules-22-00924-sch010){ref-type="scheme"}) were tested in a SRB assay for cytotoxicity screening on 12 tumor cell lines and mouse embryonic fibroblasts (NIH3T3) which showed that **GA** and compound **113** nearly had the same activity on tumor cells, but after esterification at C-30, compounds **1** and **114** showed a relatively high cytotoxicity against the tested tumor cell lines. For the fibroblasts and most of the tumor cell lines, the toxicity of compound **114** was reduced, while the cytotoxic effect on the tumor cells of compounds **12** and **115** was similar to their effect on NIH3T3 cells. However, according to Lin et al. \[[@B51-molecules-22-00924]\], when **GA** was converted into **11-DOGA**, it showed higher toxicity toward gastric cancer cells both in vivo and in vitro, so the relation between the existence of the C-11 ketone group and the apoptotic activity should be further studied. The cytotoxicity (IC~50~ values in μM) of **1**, **12**, **113**--**115** in a panel of various cancer cell lines is summarized in [Table 11](#molecules-22-00924-t011){ref-type="table"}.

2.3. Structural Modifications on Ring-E {#sec2dot3-molecules-22-00924}
---------------------------------------

The C-30 position in **GA** has been widely exploited and hundreds of derivatives have been reported in the literature. To increase the antitumor activity of **GA** and to obtain potent cytostatic compounds, Lallemand et al. \[[@B52-molecules-22-00924]\] synthesized a series of **GA** amide derivatives **116**--**130** ([Scheme 11](#molecules-22-00924-sch011){ref-type="scheme"}) by coupling **GA** with various amines. The antitumor activity screening showed that compound **127** appeared to be the most potent one, with single-digit micro molarity IC~50~ values in a panel of eight cancer cell lines. Further pharmacokinetic studies by the same group suggested that compound **127** was rapidly distributed (t~1/2~dist of \~3 min) but slowly eliminated (t~1/2~elim = \~77 min). This study was helpful in producing this kind of **GA** antitumor derivatives.

Similarly, Shi et al. \[[@B53-molecules-22-00924]\] synthesized biotinylated **GA** (**BGA**) by introducing biotin into the C-30 carboxyl of **GA**, and evaluated its antitumor effects on mouse B16 melanoma cells and BEL 7402 cells. The result showed that the biotin group in **BGA** had no influence on the antitumor effects of **GA**. The cytotoxicity (IC~50~ values in μM) of **116**--**130** in a panel of various cancer cell lines is summarized in [Table 12](#molecules-22-00924-t012){ref-type="table"}.

Guided by previous results indicating that incorporation of a stable nitroxyl radical or amino acids into antitumor molecules could increase their activity and decrease their toxicity \[[@B34-molecules-22-00924],[@B54-molecules-22-00924],[@B55-molecules-22-00924]\], Liu et al. \[[@B56-molecules-22-00924]\] designed and synthesized a series of **GA** derivatives **131**--**140** ([Scheme 12](#molecules-22-00924-sch012){ref-type="scheme"}) by introducing a nitroxyl functionality and amino acid segments into **GA**.

The in vitro cytotoxicity screening showed that compounds **131**--**140** with only various free amino acids at C-30 showed no significant cytotoxicity (GI~50~ \> 70 µM). However, incorporation of a piperidine (compounds **141**--**150**) or pyrroline (compounds **151**--**155**) nitroxyl radical at the terminus of the C-30 side chains could significantly enhance the cytotoxic effects. Among the new derivatives, compound **150** with a tryptophan amino moiety and a piperidine nitroxyl radical showed the greatest cytotoxicity (GI~50~ 13.7--15.0 µM), five-fold more potent than **GA**. These results suggested that the incorporation of a nitroxyl functionality and amino acid segments into the C-30 carboxyl group of **GA** might contribute to improve its cytotoxicity. The cytotoxicity (GI~50~ values in μM) of **141**--**155** in a panel of various cancer cell lines is summarized in [Table 13](#molecules-22-00924-t013){ref-type="table"}.

Inspired by previous studies indicating that esterification of glycyrrhetinic acid (**GA**) with dehydrozingerone (**DZ**) resulted in a novel cytotoxic **GA**--**DZ** conjugate, Tatsuzaki et al. \[[@B57-molecules-22-00924]\] synthesized a series of triterpenoid---dehydrozingerone derivatives by combining **DZ** analogs with different triterpenoids, such as oleanoic acid (**OA**), ursolic acid (**UA**), glycyrrhetinic acid (**GA**).

The in vitro antitumor assay indicated that most of the **GA**--**DZ** conjugates **156**--**166** ([Scheme 13](#molecules-22-00924-sch013){ref-type="scheme"}) showed significant antitumor activity. In particular, compounds **156**--**158** exhibited prominent cytotoxicity against LN-Cap, 1A9, and KB cells with ED~50~ values of 0.6, 0.8 and 0.9 µM. However, similar conjugates between **DZ** and **OA** or **UA** were inactive suggesting that the **GA** component was critical for activity. The cytotoxicity (ED~50~ values in μM) of **156**--**166** in a panel of various cancer cell lines is summarized in [Table 14](#molecules-22-00924-t014){ref-type="table"}.

In the search of new **GA** derivatives as antitumor agents, Csuk et al. \[[@B58-molecules-22-00924]\] performed some variations at C-30 of **GA**, including esterification, the formation of amides and a nitrile. The antitumor evaluation showed the amide derivatives like compounds **167**--**169** ([Scheme 14](#molecules-22-00924-sch014){ref-type="scheme"}) showed no cytotoxic activity at 30 µM concentration, but nearly all the ester derivatives like compounds **170**, **172**--**174** ([Scheme 15](#molecules-22-00924-sch015){ref-type="scheme"}) exhibited high cytotoxic activity. In particular, compound **172** exhibited potent cytotoxic activity on SW1736 cells (IC~50~ = 1.88 µM), while compound **175** esterified at C-30 and etherified at C-3 almost showed no cytotoxic activity (IC~50~ \> 30 µM) against seven tested human tumor cell lines. This suggested that not only the type of the chemical bonding but also the position of substituent groups affects the antitumor activity. This study greatly enriched the modification strategy of the carbonyl group. The cytotoxicity (IC~50~ values in μM) of **167**--**175** in a panel of various cancer cell lines is summarized in [Table 15](#molecules-22-00924-t015){ref-type="table"}.

2.4. Structural Modifications of Multiple Rings {#sec2dot4-molecules-22-00924}
-----------------------------------------------

In an attempt to improve the pharmacological activity of **GA**, structural modification at multiple rings has been reported. Structural modifications of multiple rings in **GA** has focused on the A, C, and E rings, especially at A and E ring. Shen et al. \[[@B59-molecules-22-00924],[@B60-molecules-22-00924]\] reported syntheses and antitumor activity of some **GA** derivatives by simultaneously modifying the C-3 hydroxyl group and the C-30 carboxyl group in **GA**. They found when the carbon chain of the linking group was 2 to 4, the activity increased as the carbon chain was lengthened, while when the carbon chain length of the linking group was 5, the activity decreased. Meanwhile, they also found that when there were nitrate moieties at C-3 and C-30 simultaneously; the antitumor activity of the compounds was enhanced.

Starting from **GA**, Li et al. \[[@B61-molecules-22-00924]\] synthesized a series of **GA** derivatives **176**--**199** ([Scheme 16](#molecules-22-00924-sch016){ref-type="scheme"}) in which the 30-carboxyl group was modificated by ferulic acid analogs and the 3-hydroxyl group was coupled with amino acids. The MTT assay results showed that most of the derivatives exhibited much higher antitumor activity than **GA** against cancer cell lines (MCF-7 cells, MDA-MB-231) and lower cytotoxicity against normal cells (hTERT-RPE1 cells).

Among the derivatives, compound **193** was the most active one (IC~50~ 1.88 + 0.20 µM for MCF-7; IC~50~ 1.37 + 0.18 µM for MDA-MB-231). The results displayed that introduction of a lipophilic fragment or amino acid groups into C-3 and C-30 might increase the antitumor activity. The cytotoxicity (IC~50~ values in μM) of **176**--**199** in a panel of various cancer cell lines is summarized in [Table 16](#molecules-22-00924-t016){ref-type="table"}.

In order to further improve the antitumor activity of **GA**, Song et al. \[[@B62-molecules-22-00924]\] designed and synthesized a series of novel **GA** derivatives by modifying the structure at the C-3 hydroxyl or C-11 carbonyl or C-30 carboxyl.

The biological activity evaluation showed that compound **203** ([Scheme 17](#molecules-22-00924-sch017){ref-type="scheme"}) exhibited the most promising antitumor activity against tumor cell lines MDA-MB-231 cells, DU-145 cells and Hep-G2 cells (IC~50~ 10.01 µM for HepG2, 11.96 µM for DU-145 and 17.8 µM for MDA-MB-231), which was much better than starting material **GA** (IC~50~ values of 74.35, 69.40, 72.65 µM, respectively). What's more, compound **200** with linker *n* = 2 and compound **205** with linker *n* = 4 also showed higher antitumor activity than **GA** on all tested tumor cell lines. But other compound, such as **201**, **202**, **204**, showed weak anti-proliferative effect due to their poor solubility. The cytotoxicity (IC~50~ values in μM) of **200**--**206**, **209**, **210** in a panel of various cancer cell lines is summarized in [Table 17](#molecules-22-00924-t017){ref-type="table"}.

3. Conclusions {#sec3-molecules-22-00924}
==============

Glycyrrhetinic Acid was found to possess remarkable anti-proliferative and apoptosis-inducing activity against various cancer cell lines. A number of structural modifications of **GA** were carried out to synthesize new potential antitumor agents. As for the many synthetic strategies reported in this review, they can be summarized as follows: (i) introduction of aminoalkyl, amino acid, sugar and other groups into the hydroxyl group at C-3 by esterification; (ii) oxidation or elimination of the hydroxyl group at C-3, introduction of functional groups at C-2, opening or increasing the number of atoms of ring-A; (iii) elimination of the C-11 ketone group in ring-C; (iv) esterification or amidation of the carboxyl group at C-30 in ring-E; (v) esterification at the C-3 hydroxyl group and C-30 carboxyl group simultaneously, elimination of the ketone group at C-11 and esterification at C-30 simultaneously.

To some extent, the reported **GA** derivatives and their biological activity confirmed that there are many factors affecting the antitumor activity, such as the kind, quantity and position of substituents, and the type of chemical bonding. The published studies of **GA** derivatives as the antitumor agents have provided us much useful information which was as follows and is summarized in [Figure 4](#molecules-22-00924-f004){ref-type="fig"}: The hydroxyl at the C-3 position seems to be critical in maintaining the cytotoxicity. The introduction of an extra amino acid or a nitrogen-containing substituent was found to be beneficial to increase the cytotoxicity, but the acetylation or oxidation of the hydroxyl group at the C-3 position resulted in a decreased anti-proliferative activity.The A ring skeleton plays an important role in eliciting antitumor activity. A cyano or trifluoromethyl substituent at C-2 position of **GA** improved the cytotoxicity. Expansion of ring A did not make a major difference in the cytotoxicity, but the number and location of hydroxyl groups in the A-ring has an important influence on the antitumor activity.The C-11 keto group of C ring seems to show no direct relation with cytotoxicity.The C-30 carboxyl group is essential for cytotoxicity. Esterification at the C-30 carboxylic acid could improve the antitumor efficacy.Esterification at the C-3 hydroxyl group and C-30 carboxyl group simultaneously increased the antitumor activity.

The chemical methods for the structural modifications of **GA** are efficient but the strategies were long and complicated and often involve harsh reaction conditions, therefore, in the future studies structure-activity relationships should be a prerequisite and focused on obtaining highly effective and low-toxicity antitumor derivatives of **GA**.
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![Structure of glycyrrhetinic acid.](molecules-22-00924-g001){#molecules-22-00924-f001}

![Synthesis of the **GA** amino alkyl derivatives **1**--**11**. *Reagents and conditions*: (a) K~2~CO~3~,CH~3~I, DMF, 24 h, 25 °C; (b) ClCH~2~COCl, Et~3~N, THF (or CH~2~Cl~2~), 25 °C, 12 h; (c) H~2~N-(CH~2~)*~n~*-NH~2~, DMF, K~2~CO~3~, 12 h, 25 °C.](molecules-22-00924-sch001){#molecules-22-00924-sch001}

![Synthesis of the **GA** amino acid derivatives **12**--**32**. *Reagents and conditions*: (a) K~2~CO~3~, alkyl halides, DMF, 24 h, 25 °C; (b) These compounds were synthesized by DCC mediated esterification of N-Boc protected amino acids followed by their deportation using TFA in dry DCM (for the amines) or by treating them with dry HCl gas in DCM (for the ammonium hydrochlorides).](molecules-22-00924-sch002){#molecules-22-00924-sch002}

![Synthesis of the **GA** amino acid derivatives **33**--**44**. *Reagents and conditions*: (a) DCC, DMAP, Boc-Asp(OBzl)OH or Boc-Glu(OBzl)OH, DCM, 12 h, 25 °C; (b) TFA, DCM, 12 h, 25 °C; (c) NH~4~^+^HCO~2~^−^, Pd/C (10%), THF/MeOH, 12 h, 25 °C; (d) HCl (gas), DCM, 12 h, 25 °C; (e) CH~3~I, K~2~CO~3~, DMF, 2 h, 25 °C.](molecules-22-00924-sch003){#molecules-22-00924-sch003}

![Synthesis of the **GA**--**Me** (**GA** methyl ester**)** amino ester derivatives **45**--**59**. *Reagents and conditions*: (a) Boc-amino acids, DCM, DMAP, DCC, 12 h, 25 °C; (b) TFA in DCM, 12 h, 25 °C, or HCl (gas) in DCM, 12 h, 25 °C.](molecules-22-00924-sch004){#molecules-22-00924-sch004}

![Synthesis of the **GA** glycosides derivatives **60**--**66**. *Reagents and conditions*: (a) Sugar trichloro acetimidate, TMSOTf, DCM, −70 °C--25 °C, 2 h.](molecules-22-00924-sch005){#molecules-22-00924-sch005}

![Synthesis of the **GA** furan-based nitric oxide (NO)-releasing derivatives **67**--**74**. *Reagents and conditions*: (a) CH~3~OH, *p*-TSA; (b) succinic anhydride, DMAP, dry DCM, 15 h; (c) phenylsulfonyl furans, DCC, DMAP, dry DCM, 24 h.](molecules-22-00924-sch006){#molecules-22-00924-sch006}

![Structures of **GA-1**, **GA-2** and **GA-3**.](molecules-22-00924-g002){#molecules-22-00924-f002}

![Structures of **CDDO**, **CDDO-Me**, **β-CDODA** and **β-CDODA-Me**.](molecules-22-00924-g003){#molecules-22-00924-f003}

![Synthesis of the **GA** 2-substituted derivatives **75**--**79**. *Reagents and conditions*: (a) CH~2~N~2~, Et~2~O, 0 °C; (b) IBX, DMSO, 21 h, 80--85 °C; (c) iodine, pyridine, tetrahydrofuran; (d) CuCN, NMP, 2 h, 130 °C; (e) CH~3~SO~2~Na, CuI, DMSO, 20 h, 120--125 °C; (f) CuI, methyl-2,2-difluoro-2-(fluorosulfonyl) acetate, DMF/HMPT, 20 h, 70 °C; (g) dimethyl phosphite, Cs~2~CO~3~, *N*,*N*-dimethylethylenediamine, toluene, 26 h, 95--100 °C.](molecules-22-00924-sch007){#molecules-22-00924-sch007}

![Synthesis of the C-2 and C-3 modified **GA** derivatives **80**--**97**. *Reagents and conditions*: (a) AcCl, pyridine, CH~2~Cl~2~, 2 h, 25 °C; (b) Jones reagent, 20--60 min, 25 °C; (c) KOH, hydrazine, ethylene glycol, 24 h, 200 °C; (d) periodic acid, DMSO, 3 days, −50 °C; (e) HOAc, p-TsOH, 24 h, 80 °C; (f) MeSO~2~Cl, pyridine (or Et~3~N for 15), 1--70 h, 25 °C; (g) for 92: K~2~CO~3~, DMF, 24 h, 120 °C; for 93: Bu~4~NF, DMF, 4 days, 102 °C; for 94: PPh3, 3,3-dimethylglutarimide, DEAD, THF, 24 h, 25 °C; (h) *m*-CPBA, CH~2~Cl~2~, 20 h, 25 °C; (i) 1,1′-thiocarbonyldiimidazole, 1,2-dichloroethane, 70 h, 100 °C; (j) Bu~3~SnH, AIBN (cat.), toluene, 40 h, 115 °C.](molecules-22-00924-sch008){#molecules-22-00924-sch008}

![Synthesis of ring A modified **GA** derivatives **98**--**112**. *Reagents and conditions*: (a) Jones' reagent; (b) HCO~2~Et, NaOMe; (c) NaOMe, H~2~O~2~; (d) *t*-BuOK/*t*-BuOH, *n*-BuONO; (e) NaBH~4~; (f) *p*-TsCl; (g) CH~3~I, K~2~CO~3~; (h) LiBr, Li~2~CO~3~; (i) *m*-CPBA, K~2~CO~3~; (j) HClO~4~; (k) KOH; (l) *m*-CPBA, NaHCO~3~; (m) NaOMe; (n) NH~2~OH·HCl; (o) p-TsCl, DMAP.](molecules-22-00924-sch009){#molecules-22-00924-sch009}

![Synthesis of ring C modified **GA** derivatives **113**--**115**. *Reagents and conditions*: (a) Zinc dust, conc. HCl, dioxane, 25 °C, 24 h; (b) MeI, K~2~CO~3~, DMF, 25 °C, 24 h; (c) BH~3~-THF, THF, citric acid, 25 °C, 20 h; (d) EtI, K~2~CO~3~, DMF, 25 °C, 24 h; (e) BH~3~-THF, THF, Na~2~CO~3~, 25 °C, 4 days.](molecules-22-00924-sch010){#molecules-22-00924-sch010}

![Synthesis of ring E modified **GA** derivatives **116**--**130**. *Reagents and conditions*: (a) 1. DCC, HOBt, DIPEA, DMF, r.t., 30 min; 2. R~1~NH~2~, r.t., overnight; (b) 1. DCC, HOBt, DIPEA, DMF, r.t., 30 min; 2. H~2~N(CH~2~)~2~NHBoc, r.t., overnight; (c) TFA, DCM, 0 °C, 3 h; (d) DMAP, RCOCl, DCM; (e) THF, RNCO, r.t., 20 h; (f) THF, RNCS, r.t., 20 h; (g) Jones reagent, acetone, 0 °C, 45 min.](molecules-22-00924-sch011){#molecules-22-00924-sch011}

![Synthesis of ring E modified **GA** derivatives **131**--**155**. *Reagents and conditions*: (a) (i) amino acid methyl ester EDCI/HOBt/Et~3~N, DMF; (ii) 4N NaOH THF/MeOH; (b) EDCI/HOBt/Et~3~N DMF, r.t., overnight; (c) EDCI/HOBt/Et~3~N DMF, r.t., overnight.](molecules-22-00924-sch012){#molecules-22-00924-sch012}

![Syntheses of GA--DZ derivatives **156**--**166**. *Reagents and conditions*: (a) ![](molecules-22-00924-i001.jpg), 1N NaOH (for R~2~ = Me), 5N KOH (for R~2~ = Ph); (b) GA, EDCI, DMAP, CH~2~Cl~2~.](molecules-22-00924-sch013){#molecules-22-00924-sch013}

![Synthesis of the **GA** amide derivatives **167**--**169**. *Reagents and conditions*: (a) K~2~CO~3~, diamine, DMF, 25 °C, 20 h; (b) Boc~2~O, Et~3~N, MeOH, 25 °C, 20 h.](molecules-22-00924-sch014){#molecules-22-00924-sch014}

![Synthesis of the **GA** ester derivatives **170**--**175**. *Reagents and conditions*: (a) K~2~CO~3~, alkyl halide, DMF, 25 °C, 20 h.](molecules-22-00924-sch015){#molecules-22-00924-sch015}

![Synthesis of multiple rings modified **GA** derivatives **176**--**199**. *Reagents and conditions*: (a) ferulic acid analogs, EDCI, DMAP, CH~2~Cl~2~, r.t.; (b) Boc-L-methionine or Boc-L-selenomethionine, EDCI, DMAP, CH~2~Cl~2~, r.t.; (c) HCl (gas) in CH~2~Cl~2~, r.t.](molecules-22-00924-sch016){#molecules-22-00924-sch016}

![Synthesis of multiple rings modified **GA** derivatives **200**--**210**: *Reagents and conditions*: (a) K~2~CO~3~, cat. KI, 60 °C, 12 h, chromatography; (b) Ac~2~O, Py, r.t., 3 h, chromatography; (c) K~2~CO~3~, cat. KI, 224, or 225 or 226, 60 °C, 12 h; (d) Zn (containing 10% HgCl~2~), concentrated. HCl, 1,4-dioxane, 20 °C, 2 h, chromatography; (e) K~2~CO~3~, cat. KI, 227, 60 °C, 12 h, chromatography; (f) ClCH~2~COCl, Py, THF, r.t., 4 h; (g) Et~3~N, THF, refluxing, 10 h; (h) K~2~CO~3~, cat. KI 230 or 231 60 °C, 12 h, chromatography.](molecules-22-00924-sch017){#molecules-22-00924-sch017}

![Structure-activity relationships of GA.](molecules-22-00924-g004){#molecules-22-00924-f004}

molecules-22-00924-t001_Table 1

###### 

Cytotoxicity (IC~50~ values in µM) of **1**--**11** in a panel of various cancer cell lines.

  Cell Lines   GA      1       2       3       4      5      6      7      8      9      10     11
  ------------ ------- ------- ------- ------- ------ ------ ------ ------ ------ ------ ------ ------
  518A2        83.92   27.54   25.43   5.24    3.79   2.55   2.02   1.09   1.27   3.49   3.12   4.33
  8505C        86.50   26.07   26.08   15.86   3.37   2.12   1.78   1.68   2.13   3.35   6.18   7.60
  A253         80.78   19.42   25.54   6.19    3.64   2.56   2.27   1.12   1.74   3.01   4.65   5.48
  A2780        74.57   25.54   23.77   6.01    4.39   2.43   2.00   1.36   1.14   2.80   3.30   3.63
  A549         82.76   23.50   24.80   8.39    5.15   3.31   2.52   1.59   2.21   4.08   2.23   5.16
  DLD-1        81.21   26.12   17.36   6.13    4.39   2.66   2.40   0.91   1.25   3.96   4.50   5.53
  FADU         84.55   23.41   23.56   12.44   5.57   3.51   3.30   1.78   2.20   4.26   5.54   5.65
  HCT-11       78.83   22.10   14.41   5.13    4.30   2.41   2.19   1.17   1.70   3.53   3.44   3.86
  HCT-8        78.85   24.36   13.39   3.97    2.37   1.51   1.38   0.62   0.89   2.92   2.42   4.07
  HT-29        80.09   27.54   16.91   5.34    2.90   1.69   1.28   0.59   0.86   2.76   2.06   2.73
  LIPO         81.44   20.47   25.39   14.55   3.89   2.57   1.93   1.59   1.44   4.36   5.48   6.93
  MCF-7        84.70   22.14   25.22   6.69    3.55   2.45   1.79   1.17   0.98   3.89   3.33   2.68
  SW1736       76.93   34.87   16.42   3.14    6.05   3.30   2.69   1.61   2.24   4.09   3.30   3.73
  SW480        86.80   16.08   25.91   8.92    3.68   2.54   1.91   2.25   2.24   3.93   5.74   4.73
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###### 

Cytotoxicity (IC~50~ values in µM) of **12**--**32** in a panel of various cancer cell lines.

  Compound   8505C          A253           A2780          A549           DLD-1          LIPO           Average
  ---------- -------------- -------------- -------------- -------------- -------------- -------------- --------------
  **GA**     86.50 ± 4.20   80.78 ± 4.04   74.57 ± 3.73   82.76 ± 4.14   81.21 ± 4.06   81.44 ± 4.07   81.4 ± 4.07
  **12**     24.58 ± 1.23   25.04 ± 1.25   26.96 ± 1.35   22.74 ± 1.14   28.14 ± 1.41   27.66 ± 1.38   24.39 ± 1.22
  **13**     14.24 ± 0.71   15.76 ± 0.79   24.95 ± 1.25   14.41 ± 0.72   27.61 ± 1.38   15.93 ± 0.80   19.21 ± 0.96
  **14**     8.10 ± 0.41    10.67 ± 0.54   20.32 ± 1.18   6.15 ± 0.31    22.69 ± 1.13   11.54 ± 0.80   13.76 ± 0.69
  **15**     \>30           \>30           \>30           \>30           \>30           \>30           \>30
  **16**     \>30           \>30           \>30           \>30           \>30           \>30           \>30
  **17**     \>30           \>30           \>30           \>30           \>30           \>30           \>30
  **18**     7.45 ± 0.37    6.26 ± 0.31    5.99 ± 0.30    6.42 ± 0.32    8.59 ± 0.43    7.54 ± 0.38    7.04 ± 0.35
  **19**     4.31 ± 0.22    3.61 ± 0.18    2.98 ± 0.15    2.77 ± 0.14    4.49 ± 0.22    4.30 ± 0.22    3.74 ± 0.19
  **20**     2.55 ± 0.13    2.50 ± 0.13    1.72 ± 0.09    2.40 ± 0.12    2.51 ± 0.13    2.52 ± 0.13    2.37 ± 0.12
  **21**     5.32 ± 0.27    3.59 ± 0.18    3.90 ± 0.20    5.39 ± 0.27    5.61 ± 0.28    4.32 ± 0.22    4.69 ± 0.23
  **22**     3.87 ± 0.19    2.33 ± 0.12    2.59 ± 0.13    3.43 ± 0.17    3.72 ± 0.19    2.74 ± 0.14    3.11 ± 0.16
  **23**     2.32 ± 0.12    2.23 ± 0.11    1.77 ± 0.09    2.18 ± 0.11    2.74 ± 0.14    2.38 ± 0.12    2.27 ± 0.11
  **24**     2.76 ± 0.14    2.01 ± 0.10    2.24 ± 0.11    2.65 ± 0.13    2.54 ± 0.13    2.74 ± 0.14    2.49 ± 0.12
  **25**     3.49 ± 0.17    3.51 ± 0.18    2.08 ± 0.10    3.43 ± 0.17    5.54 ± 0.28    3.53 ± 0.18    3.60 ± 0.18
  **26**     1.96 ± 0.10    2.68 ± 0.13    1.31 ± 0.07    1.78 ± 0.09    3.52 ± 0.18    3.49 ± 0.17    2.46 ± 0.12
  **27**     4.79 ± 0.24    5.03 ± 0.25    3.54 ± 0.18    5.07 ± 0.25    4.54 ± 0.23    4.81 ± 0.24    4.63 ± 0.23
  **28**     3.10 ± 0.16    3.49 ± 0.17    2.85 ± 0.14    3.51 ± 0.18    5.02 ± 0.25    3.57 ± 0.18    3.59 ± 0.18
  **29**     3.19 ± 0.16    3.05 ± 0.15    1.73 ± 0.09    2.76 ± 0.14    4.54 ± 0.23    3.25 ± 0.16    3.09 ± 0.15
  **30**     \>30           \>30           \>30           \>30           \>30           \>30           \>30
  **31**     \>30           \>30           \>30           \>30           \>30           \>30           \>30
  **32**     \>30           \>30           \>30           \>30           \>30           \>30           \>30
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###### 

Cytotoxicity (IC~50~ values in µM) of **33**--**40**, **43**, **44** in a panel of various cancer cell lines.

  Cell Lines   35             36             37             38             39      40      43             44
  ------------ -------------- -------------- -------------- -------------- ------- ------- -------------- --------------
  518A2        10.90 ± 0.55   1.75 ± 0.09    17.19 ± 0.86   17.94 ± 0.90   \>100   \>100   39.24 ± 1.96   47.72 ± 2.39
  8505C        12.97 ± 0.45   1.76 ± 0.09    15.82 ± 0.79   17.00 ± 0.85   \>100   \>100   45.36 ± 2.27   61.57 ± 3.08
  A253         7.99 ± 0.40    1.28 ± 0.06    15.07 ± 0.75   13.80 ± 0.69   \>100   \>100   30.47 ± 1.52   53.07 ± 2.65
  A2780        8.84 ± 0.44    1.65 ± 0.08    17.29 ± 0.86   18.24 ± 0.91   \>100   \>100   22.44 ± 1.12   29.19 ± 1.46
  A549         10.94 ± 0.55   1.77 ± 0.09    19.82 ± 0.99   21.20 ± 1.06   \>100   \>100   31.59 ± 1.58   60.96 ± 3.05
  Lipo         11.35 ± 0.57   1.74 ± 0.09    16.67 ± 0.83   18.78 ± 0.94   \>100   \>100   40.62 ± 2.03   54.77 ± 2.74
  MCF-7        7.35 ± 0.36    1.27 ± 0.06    17.47 ± 0.87   16.96 ± 0.85   \>100   \>100   16.89 ± 0.84   29.26 ± 1.46
  SW1736       16.68 ± 0.83   2.33 ± 0.12    17.13 ± 0.86   19.24 ± 0.96   \>100   \>100   20.85 ± 1.04   38.50 ± 1.93
  Average      10.88 ± 0.54   1.69 ± 0.08    17.06 ± 0.85   17.90 ± 0.90   \>100   \>100   30.93 ± 1.55   46.77 ± 2.34
  NiH3T3       14.74 ± 0.74   39.09 ± 1.95   23.09 ± 1.15   24.42 ± 1.22   \>100   \>100   16.89 ± 0.84   33.63 ± 1.68
  F            1.35           23.13          1.35           1.36                           0.55           0.72
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###### 

Cytotoxicity (IC~50~ values in µM) of **45**--**59** in a panel of various cancer cell lines.

  Compound   8505C   A253   A2780   A549    DLD-1   LIPO    MCF-7
  ---------- ------- ------ ------- ------- ------- ------- -------
  **45**     2.92    2.26   2.24    2.26    3.35    3.56    2.25
  **46**     2.50    2.46   1.83    2.13    3.42    2.50    2.49
  **47**     9.62    5.56   4.58    6.91    11.64   7.96    5.49
  **48**     16.93   6.41   5.50    9.94    8.70    16.15   4.60
  **49**     11.47   7.48   12.56   14.48   12.45   22.32   6.06
  **50**     \>30    \>30   6.89    \>30    \>30    \>30    \>30
  **51**     \>30    \>30   \>30    \>30    \>30    \>30    \>30
  **52**     \>30    \>30   \>30    \>30    \>30    \>30    \>30
  **53**     3.47    3.41   2.13    3.39    3.41    3.54    2.73
  **54**     3.52    3.52   2.48    3.38    4.49    4.54    3.40
  **55**     5.48    4.05   4.94    5.43    6.27    5.95    4.03
  **56**     4.02    3.76   4.06    3.88    4.38    4.02    2.46
  **57**     2.89    4.04   2.59    2.35    1.48    0.80    3.01
  **58**     2.49    2.21   1.98    2.53    3.01    2.70    1.55
  **59**     2.40    2.43   1.58    2.43    2.27    2.51    1.75

molecules-22-00924-t005_Table 5

###### 

Cytotoxicity (IC~50~ values in µM) of **60**--**66** in a panel of various cancer cell lines (NA = not active).

  Cell Lines   60   61           62            63            64            65            66   GA--Me
  ------------ ---- ------------ ------------- ------------- ------------- ------------- ---- -------------
  SW1736       NA   NA           NA.           23.87 ± 1.3   11.18 ± 0.9   21.38 ± 1.9   NA   34.87 ± 1.2
  MCF-7        NA   16.7 ± 1.4   19.60 ± 1.4   NA            9.48 ± 1.4    20.11 ± 1.3   NA   22.14 ± 0.9
  LIPO         NA   NA           NA            28.45 ± 2.1   NA            23.23 ± 1.3   NA   20.47 ± 1.1
  DLD-1        NA   NA           NA            NA            NA            23.18 ± 1.7   NA   26.12 ± 1.0
  A253         NA   NA           NA            27.25 ± 1.8   13.16 ± 0.9   19.70 ± 1.4   NA   19.42 ± 1.1
  8505C        NA   NA           NA            NA            21.97 ± 0.6   22.77 ± 1.4   NA   26.07 ± 1.3
  518A2        NA   NA           NA            28.92 ± 2.0   25.95 ± 0.8   23.26 ± 1.2   NA   27.54 ± 1.0
  NiH3T3       NA   NA           NA            NA            NA            23.45 ± 0.1   NA   22.81 ± 0.6
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###### 

Cytotoxicity (IC~50~ values in µM) of **68**--**74** in a panel of various cancer cell lines.

  Cell Lines   GA     68      69      70      71      72      73     74
  ------------ ------ ------- ------- ------- ------- ------- ------ ------
  HepG2        \>50   18.18   13.41   26.03   36.52   15.67   7.90   2.90
  BEL-7402     \>50   7.85    9.22    6.03    8.20    19.92   7.37   2.94
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###### 

Cytotoxicity (IC~50~ values in μM) of **GA-1**, **GA-2** and **GA-3** in A-549.

  Cell Lines   GA-1    GA-2    GA-3
  ------------ ------- ------- -------
  A549         1.182   1.044   1.274

molecules-22-00924-t008_Table 8

###### 

Cytotoxicity (IC~50~ values in μM) of **76**--**79** and **β-CDODA-Me** in a panel of various cancer cell lines.

  Compound         253JB-V   KU7    Panc-1   Panc-28
  ---------------- --------- ------ -------- ---------
  **76**           2.67      3.04   4.08     12.75
  **77**           11.97     3.34   7.69     9.75
  **78**           0.67      0.38   0.82     1.14
  **79**           7.90      3.73   6.11     8.14
  **β-CDODA-Me**   0.25      1.59   1.22     1.80

molecules-22-00924-t009_Table 9

###### 

Cytotoxicity (IC~50~ values in μM) of **80**--**95**, **97** in a panel of various cancer cell lines.

  Compound     518A2   8505C   A2780   A549    DLD-1   LIPO    MCF-7   SW1736
  ------------ ------- ------- ------- ------- ------- ------- ------- --------
  **80--85**   \>30    \>30    \>30    \>30    \>30    \>30    \>30    \>30
  **86**       18.33   19.28   28.83   \>30    \>30    28.74   21.87   16.56
  **87**       29.82   27.69   14.84   26.62   29.56   24.80   28.68   27.00
  **88**       \>30    \>30    \>30    \>30    \>30    \>30    \>30    13.24
  **89**       \>30    29.42   \>30    \>30    \>30    \>30    \>30    29.40
  **90--92**   \>30    \>30    \>30    \>30    \>30    \>30    \>30    \>30
  **93**       \>30    \>30    14.95   \>30    \>30    \>30    \>30    19.14
  **94, 95**   \>30    \>30    \>30    \>30    \>30    \>30    \>30    \>30
  **97**       23.69   24.30   10.39   \>30    \>30    25.52   \>30    16.98
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###### 

Cytotoxicity (IC~50~ values in μM) of **98**--**112** in a panel of various cancer cell lines.

  Cell Lines   98      99      100     101     102     103     104     105
  ------------ ------- ------- ------- ------- ------- ------- ------- ------
  HepG-2       61.70   \>100   71.83   47.12   \>100   \>100   \>100   0.22
               106     107     108     109     110     111     112     
  HepG-2       59.98   \>100   \>100   \>100   88.68   \>100   \>100   
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###### 

Cytotoxicity (IC~50~ values in μM) of **1**, **12**, **113**--**115** in a panel of various cancer cell lines.

  Cell Lines   GA      113     1       114     12      115
  ------------ ------- ------- ------- ------- ------- -------
  518A2        83.92   71.49   27.54   34.54   25.23   51.52
  8505C        86.50   78.52   26.07   33.88   24.58   52.80
  A2780        74.57   62.78   25.54   23.58   26.96   57.01
  A431         79.58   86.13   25.28   33.55   23.45   46.55
  A549         82.76   79.13   23.50   31.59   22.74   48.97
  DLD-1        81.21   90.50   26.12   31.73   28.14   52.80
  HCT-116      78.83   87.70   22.10   31.82   21.58   47.78
  HCT-8        78.85   88.76   24.36   31.34   43.42   44.32
  HT-29        80.09   90.30   27.54   23.89   22.14   44.32
  LIPO         81.44   73.88   20.47   34.81   27.66   52.80
  MCF-7        84.70   90.19   22.14   34.37   18.61   48.97
  SW1736       76.93   72.47   34.87   32.35   13.37   45.48
  NIH3T3       18.52   68.70   22.81   42.22   23.66   43.16
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###### 

Cytotoxicity (IC~50~ values in μM) of **116**--**130** in a panel of various cancer cell lines.

  Compound   A549    SKMEL   T98G    HS683   U373   PC3   MCF7   816F10
  ---------- ------- ------- ------- ------- ------ ----- ------ --------
  **GA**     \>100   92      85      84      83     80    76     37
  **116**    52      \>100   91      59      43     34    34     37
  **117**    40      \>100   \>100   57      75     43    38     31
  **118**    33      82      46      56      42     33    31     32
  **119**    43      60      73      63      57     41    37     48
  **120**    31      \>100   \>100   58      32     31    59     30
  **121**    47      49      62      38      55     53    28     36
  **122**    63      42      77      58      75     72    46     31
  **123**    37      38      54      36      37     47    30     31
  **124**    68      35      77      67      76     72    27     31
  **125**    28      37      35      31      29     30    25     28
  **126**    29      49      30      28      30     32    28     31
  **127**    7       9       12      6       6      8     4      4
  **128**    29      65      71      42      42     46    42     41
  **129**    31      38      25      8       29     9     30     34
  **130**    38      33      35      36      35     39    30     33
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###### 

Cytotoxicity (GI~50~ values in μM) of **141**--**155** in a panel of various cancer cell lines.

  Compound   A549           DU145          KB             Kbvin
  ---------- -------------- -------------- -------------- --------------
  **GA**     61.2 ± 2.33    64.9 ± 0.505   61.2 ± 0.118   62.3 ± 1.41
  **141**    \>70           \>70           \>70           \>70
  **142**    \>70           \>70           \>70           \>70
  **143**    19.4 ± 0.909   19.3 ± 0.292   14.6 ± 0.448   14.9 ± 0.471
  **144**    34.2 ± 1.88    28.9 ± 0.921   17.5 ± 0.927   18.6 ± 0.931
  **145**    23.3 ± 0.304   21.7 ± 0.402   16.9 ± 0.501   19.2 ± 0.497
  **146**    44.0 ± 0.057   45.5 ± 0.666   39.9 ± 0.618   47.6 ± 1.06
  **147**    18.3 ± 0.373   17.4 ± 0.619   15.3 ± 0.469   19.5 ± 1.33
  **148**    \>70           \>70           \>70           \>70
  **149**    19.6 ± 1.60    22.0 ± 0.546   16.0 ± 0.368   17.0 ± 0.377
  **150**    15.0 ± 0.689   15.0 ± 0.363   14.2 ± 0.670   13.7 ± 1.25
  **151**    46.7 ± 1.90    46.2 ± 0.697   45.5 ± 1.04    46.9 ± 0.230
  **152**    46.1 ± 0.653   45.2 ± 1.27    41.3 ± 0.346   44.2 ± 0.280
  **153**    19.0 ± 1.13    22.5 ± 0.606   17.8 ± 0.193   16.6 ± 0.591
  **154**    34.5 ± 0.187   39.5 ± 1.05    30.7 ± 0.480   27.3 ± 0.338
  **155**    41.5 ± 1.83    43.2 ± 1.61    38.4 ± 1.15    38.5 ± 0.956
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###### 

Cytotoxicity (ED~50~ values in μM) of **156**--**166** in a panel of various cancer cell lines.

  Compound   KB     KB-VIN   A549   1A9    HCT-8   ZR-751   PC-3   DU-145   LN-Cap
  ---------- ------ -------- ------ ------ ------- -------- ------ -------- --------
  **GA**     \>21   \>21     NA     \>21   19.5    NA       \>21   \>21     \>21
  **DZ**     NA     NA       \>52   33.9   \>52    \>52     \>52   \>52     51
  **156**    1.6    2.5      2      0.9    1.7     2.8      1.4    3.1      0.6
  **157**    0.8    2.8      2.2    0.8    1.9     3        1.1    3.6      2.8
  **158**    0.9    1.9      2.8    1.6    2       1.9      2.8    9.9      6.5
  **159**    6.2    \>15     15.5   5.9    2.6     \>15     7.4    \>15     1.9
  **160**    1.8    1.7      1.7    1.1    2.7     5.2      3.3    5.8      1.1
  **161**    2.9    13.2     3      1.8    4.9     8.8      3.5    \>15     6.8
  **162**    3      8.7      3.2    1.3    2.2     2.7      1.6    2.7      4.4
  **163**    NA     NA       \>14   \>14   \>14    NA       \>14   \>14     \>14
  **164**    9.9    NA       \>14   13.3   \>14    \>14     14.1   \>14     14.1
  **165**    NA     NA       NA     \>14   \>14    NA       14.1   \>14     14.1
  **166**    \>14   \>14     NA     NA     \>14    NA       \>14   13       \>14

molecules-22-00924-t015_Table 15

###### 

Cytotoxicity (IC~50~ values in μM) of **167**--**175** in a panel of various cancer cell lines.

  Compound   518A2   8505C   A253    A549    DLD-1   Lipo    SW1736
  ---------- ------- ------- ------- ------- ------- ------- --------
  **GA**     83.92   86.50   80.78   82.76   81.21   81.44   76.93
  **167**    \>30    \>30    \>30    \>30    \>30    \>30    \>30
  **168**    \>30    \>30    \>30    \>30    \>30    ＞30    \>30
  **169**    \>30    \>30    \>30    \>30    \>30    \>30    \>30
  **170**    15.19   15.59   15.89   20.27   22.98   15.46   19.87
  **171**    28.99   \>30    \>30    \>30    \>30    \>30    28.64
  **172**    21.00   8.82    10.97   4.28    23.09   11.47   1.88
  **173**    14.91   11.61   13.57   19.16   14.88   12.77   16.36
  **174**    15.33   15.59   15.89   20.27   22.98   15.46   19.87
  **175**    \>30    \>30    \>30    \>30    \>30    \>30    \>30
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###### 

Cytotoxicity (IC~50~ values in μM) of **176**--**199** in a panel of various cancer cell lines.

  Compound   MCF-7          MDA-MB-231     hTERT-RPE1
  ---------- -------------- -------------- --------------
  **GA**     75.66 ± 1.52   84.70 ± 1.73   63.41 ± 1.07
  **176**    13.64 ± 0.93   5.03 ± 0.82    17.32 ± 1.21
  **177**    22.46 ± 1.26   8.14 ± 0.76    22.80 ± 0.97
  **178**    20.29 ± 1.47   14.38 ± 0.52   29.63 ± 1.16
  **179**    24.45 ± 1.36   14.46 ± 0.58   28.41 ± 0.87
  **180**    8.54 ± 0.67    7.31 ± 0.16    18.59 ± 0.54
  **181**    19.27 ± 1.01   9.41 ± 1.03    21.11 ± 0.73
  **182**    14.90 ± 0.75   20.84 ± 1.20   24.09 ± 0.88
  **183**    19.30 ± 0.98   23.15 ± 1.07   22.88 ± 0.68
  **192**    6.00 ± 0.43    3.52 ± 0.61    10.36 ± 0.80
  **193**    1.88 ± 0.20    1.37 ± 0.18    4.93 ± 0.36
  **194**    8.62 ± 0.23    5.36 ± 0.44    16.28 ± 0.51
  **195**    8.45 ± 0.32    3.49 ± 0.61    12.33 ± 0.46
  **196**    7.24 ± 0.30    6.43 ± 0.84    8.48 ± 0.73
  **197**    6.02 ± 0.35    6.27 ± 0.24    6.33 ± 0.19
  **198**    2.65 ± 0.12    2.31 ± 0.65    5.65 ± 1.02
  **199**    2.42 ± 0.23    1.86 ± 0.29    7.08 ± 0.73
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###### 

Cytotoxicity (IC~50~ values in μM) of **200**--**206**, **209** and **210** in a panel of various cancer cell lines.

  Compound   HepG2          DU-145         MDA-MB-231
  ---------- -------------- -------------- --------------
  **GA**     74.35 ± 2.03   69.40 ± 2.37   72.65 ± 1.67
  **200**    \>100          21.59 ± 3.22   24.66 ± 2.71
  **201**    \>100          \>100          89.40 ± 2.85
  **202**    \>100          \>100          \>100
  **203**    10.01 ± 2.29   11.96 ± 1.42   17.80 ± 1.76
  **204**    \>100          \>100          79.3 ± 2.34
  **205**    36.37 ± 1.89   \>100          40.65 ± 2.11
  **206**    \>100          \>100          \>100
  **209**    \>100          \>100          \>100
  **210**    \>100          \>100          \>100

[^1]: These authors contributed equally to this work.
